

Reference Number: FOI202223/003
From: Private Individual
Date: 01 April 2022
Subject: Number of Metastatic/advanced Breast cancer patients treated with a list of specific drugs

- Q1 In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
- a. Abemaciclib (Verzenios) + aromatase inhibitor *
 - b. Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
 - c. Alpelisib (Piqray) + Fulvestrant (Faslodex)
 - d. Atezolizumab (Tecentriq)**
 - e. Bevacizumab (Avastin)
 - f. Eribulin (Halaven)
 - g. Everolimus (Afinitor) + Exemestane
 - h. Fulvestrant (Faslodex) as a single agent
 - i. Gemcitabine + paclitaxel
 - j. Herceptin (Trastuzumab) + paclitaxel
 - k. Herceptin (Trastuzumab) as a single agent
 - l. Lapatinib (Tyverb)
 - m. Neratinib (Nerlynx)
 - n. Olaparib (Lynparza)
 - o. Palbociclib (Ibrance) + aromatase inhibitor*
 - p. Palbociclib (Ibrance) + Fulvestrant (Faslodex)
 - q. Pertuzumab (Perjeta) + trastuzumab + docetaxel
 - r. Ribociclib (Kisqali) + aromatase inhibitor*
 - s. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
 - t. Talazoparib (Talzenna)
 - u. Trastuzumab emtansine (Kadcyla)
 - v. Other active systemic anti-cancer therapy **
 - w. *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent
- A1 Zero. This is primarily an adult diagnosis and we have not had any patients presenting in the time scale specified.
- Q2 For the above patients, how many of these received their first ever dose for each product line?
- A2 Not applicable, as per A1 above